Oncology Medical News about Colorectal Liver

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management
Annals of Surgical Oncology, 06/12/09

Reddy SK et al. - In a review of synchronous colorectal liver metastases (CLM), it appears that the traditional treatment paradigm centering on the utility of prehepatectomy chemotherapy for resectable synchronous CLM should be reconsidered. Recent developments underscore the need for prospective randomized controlled trials evaluating the optimal timing of hepatectomy relative to chemotherapy.

Methods

Pts with synchronous CLM are typically treated with initial colorectal resection followed by arbitrary and prolonged courses of chemotherapy.
Partial hepatectomy is considered only for pts without interval disease progression.
This review describes the rationale for this treatment approach and recent developments suggesting that this management paradigm should be reconsidered.

Results

Because asymptomatic colorectal cancer often does not lead to complications, and given the potential benefit of chemotherapy in downsizing unresectable to resectable liver disease, most pts with asymptomatic primary tumors and unresectable synchronous CLM should be first treated with chemotherapy.
Initial hepatic resection should be considered for resectable synchronous CLM.
Survival benefits from prehepatectomy chemotherapy have not been established.
Several reports demonstrate morbidity after hepatic resection from extended durations of irinotecan- and/or oxaliplatin-based prehepatectomy chemotherapy.
Although shorter treatment periods may not have these deleterious effects on subsequent hepatic resection, prospective studies reveal that most pts with supposedly aggressive disease with short treatment durations will not be identified.
Complete radiologic response to prehepatectomy chemotherapy is not only rare but also does not equate with a complete pathological response.
Several studies suggest that simultaneous colorectal and minor hepatic resections can performed safely with benefits in total morbidity when compared with traditional staged procedures.

<< Previous
HDAC inhibitor-based therapies and haematological malignancy

Next >>
Risk factors for complications after laparoscopic surgery in...